'We need to do more': Merck CEO Rob Davis highlights M&A, deals strategy ahead of '28 Keytruda patent cliff
With megablockbuster Keytruda’s patent cliff looming in 2028, Merck has made some bold M&A moves in an attempt to find its next big moneymaker, including last year’s $11.5 billion acquisition of Acceleron. According to CEO Robert Davis, there’s plenty more of that coming in 2022.
The chief executive highlighted the Acceleron deal — in which the pharma giant snapped up the potential blockbuster pulmonary arterial hypertension (PAH) drug sotatercept — and last year’s Pandion Therapeutics acquisition as examples of the company’s approach going into the new year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.